Aspiriant LLC’s Vanguard Morningstar Mid-Cap Value ETF VOE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$351K Sell
1,793
-2,056
-53% -$420K 0.01% 287
2026
Q2
$761K Hold
3,849
– – 0.02% 201
2026
Q1
$709K Hold
3,849
– – 0.02% 186
2025
Q4
$683K Buy
3,849
+177
+5% +$31K 0.02% 186
2025
Q3
$641K Hold
3,672
– – 0.02% 183
2025
Q2
$604K Hold
3,672
– – 0.02% 184
2025
Q1
$590K Hold
3,672
– – 0.02% 175
2024
Q4
$594K Sell
3,672
-88
-2% -$14.8K 0.02% 175
2024
Q3
$630K Hold
3,760
– – 0.02% 176
2024
Q2
$566K Buy
3,760
+2,056
+121% +$312K 0.02% 182
2024
Q1
$266K Sell
1,704
-14
-0.8% -$2.06K 0.01% 270
2023
Q4
$249K Hold
1,718
– – 0.01% 264
2023
Q3
$225K Sell
1,718
-22
-1% -$3.05K 0.01% 257
2023
Q2
$241K Sell
1,740
-760
-30% -$101K 0.01% 254
2023
Q1
$335K Buy
+2,500
New +$347K 0.02% 207

Other funds holding VOE

Aspiriant LLC's VOE Position: Q3 2026 in Review

Aspiriant LLC reduced its Vanguard Morningstar Mid-Cap Value ETF (VOE) stake by 53% in Q3 2026, selling an estimated $420K and leaving 1,793 shares worth $351K. The position accounts for 0.01% of the portfolio, ranked #287.

Aspiriant LLC first reported a position in VOE in Q1 2023 and has held it in 15 quarters since. The position peaked at $761K in Q2 2026. 1,268 funds tracked by Wall St. Rank hold VOE as of Q3 2026.

  • Aspiriant LLC held 1,793 shares of Vanguard Morningstar Mid-Cap Value ETF worth $351K as of Q3 2026.
  • Aspiriant LLC sold 2,056 Vanguard Morningstar Mid-Cap Value ETF shares in Q3 2026, an estimated $420K.
  • Vanguard Morningstar Mid-Cap Value ETF made up 0.01% of Aspiriant LLC's portfolio in Q3 2026, its #287 holding.
  • Aspiriant LLC first reported a position in Vanguard Morningstar Mid-Cap Value ETF in Q1 2023 and has held it in 15 quarters since.
  • Aspiriant LLC's Vanguard Morningstar Mid-Cap Value ETF position peaked at $761K in Q2 2026.
  • 1,268 funds tracked by Wall St. Rank held Vanguard Morningstar Mid-Cap Value ETF as of Q3 2026.

Based on Aspiriant LLC's 13F filing for Q3 2026, filed 16 Oct 2026.